Home
Market
Orion raises outlook after Merck deal on developing prostate cancer drug
Market

Orion raises outlook after Merck deal on developing prostate cancer drug

2 years ago No Comments

This post was originally published on this site

Given the upfront payment of $290 million Orion is to receive from Merck, the Finnish company now expects sales and operating profit in 2022 to be “clearly higher” than in 2021.

Related Posts

About The Author

admin
More from this Author